AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26851187 — intervention group
Group type: EXPERIMENTAL
Intervention: Naptumomab estafenatox (Nap) + IFNα
Number of subjects: 513
Study 26851187 — intervention group
Group type: COMPARATOR
Intervention: IFNα
Number of subjects: 513
Study 24216124 — intervention group
Group type: EXPERIMENTAL
Intervention: eGFR attributable to disease
Number of subjects: 6337
Study 24216124 — intervention group
Group type: EXPERIMENTAL
Intervention: eGFR attributable to normal aging
Number of subjects: 6337
Study 22108900 — intervention group
Group type: EXPERIMENTAL
Intervention: Communities That Care (CTC) prevention system
Number of subjects: 24
Study 19880586 — intervention group
Group type: EXPERIMENTAL
Intervention: Walnut-enriched ad libitum diet (56 g walnuts/day)
Number of subjects: 24
Study 19880586 — intervention group
Group type: COMPARATOR
Intervention: Ad libitum diet without walnuts
Number of subjects: 24
Study 19880586 — intervention group
Group type: EXPERIMENTAL
Intervention: Walnut-enriched diet
Number of subjects: 24
Study 17984413 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine supplementation (l-glutamine, 0.3 g/kg per day)
Number of subjects: 90
Study 17984413 — intervention group
Group type: COMPARATOR
Intervention: Control group (no glutamine supplementation)
Number of subjects: 90
Study 16167232 — intervention group
Group type: EXPERIMENTAL
Intervention: Titanoreine cream (n=133)
Number of subjects: 252
Study 16167232 — intervention group
Group type: COMPARATOR
Intervention: Compound carraghenates suppository (n=119)
Number of subjects: 252
Study 12001769 — intervention group
Group type: EXPERIMENTAL
Intervention: Underwater labor
Number of subjects: 59
Study 12001769 — intervention group
Group type: COMPARATOR
Intervention: Classical deliveries
Number of subjects: 59
Study 9469683 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-hour infusion of furosemide (0.1 mg/kg loading dose, followed by 0.9 mg/kg over 6 hours)
Number of subjects: 30
Study 9469683 — intervention group
Group type: COMPARATOR
Intervention: Bolus administration of furosemide (1 mg/kg over 2 minutes, followed by a 6-hour placebo infusion)
Number of subjects: 30
Study 7631260 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with carboplatin, ifosfamide, and etoposide followed by carboplatin and vindesine, and hyperfractionated accelerated radiotherapy (1.5 Gy 10 times per week for a total of 45 Gy in 3 weeks)
Number of subjects: 25
Study 7631260 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant treatment
Number of subjects: 25
Study 7631260 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal treatment
Number of subjects: 25
Study 2241007 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine (20 mg tid)
Number of subjects: 45
Study 2241007 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 720378 — intervention group
Group type: EXPERIMENTAL
Intervention: Noradrenaline plus propranolol 10 microgram/ml
Number of subjects: 8
Study 720378 — intervention group
Group type: EXPERIMENTAL
Intervention: Noradrenaline plus propranolol 10 microgram/ml plus oxprenolol 3 microgram/ml
Number of subjects: 8
Study 720378 — intervention group
Group type: EXPERIMENTAL
Intervention: Noradrenaline plus propranolol 13 microgram/ml
Number of subjects: 8
Study 720378 — intervention group
Group type: COMPARATOR
Intervention: Noradrenaline alone
Number of subjects: 8
Study 31985080 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (1 µg/kg) administered at the end of surgery
Number of subjects: 140
Study 31985080 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl (1 µg/kg) administered 10 to 15 minutes before the end of surgery
Number of subjects: 140
Study 31162894 — intervention group
Group type: EXPERIMENTAL
Intervention: Galavit in combination with standard therapy
Number of subjects: 60
Study 31162894 — intervention group
Group type: COMPARATOR
Intervention: Standard antibiotic therapy
Number of subjects: 60
Study 28608899 — intervention group
Group type: EXPERIMENTAL
Intervention: Clustered approach using median sensor values from groups of 6, 8, and 21 sensors
Number of subjects: 21
Study 28608899 — intervention group
Group type: COMPARATOR
Intervention: Individual sensors
Number of subjects: 21
Study 25631483 — intervention group
Group type: COMPARATOR
Intervention: Intravitreal ranibizumab (IVR)
Number of subjects: 75
Study 25631483 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab (IVB)
Number of subjects: 75
Study 23503369 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol and remifentanil
Number of subjects: 176
Study 23503369 — intervention group
Group type: EXPERIMENTAL
Intervention: Noxious stimulation
Number of subjects: 176
Study 23503369 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 176
Study 20823089 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% albumin infusion before exchange transfusion
Number of subjects: 42
Study 20823089 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 42
Study 19211182 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild hypothermia (32‐34 degrees C during 24h)
Number of subjects: 20
Study 19211182 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI evaluation
Number of subjects: 20
Study 19211182 — intervention group
Group type: EXPERIMENTAL
Intervention: Autopsy
Number of subjects: 20
Study 17314110 — intervention group
Group type: EXPERIMENTAL
Intervention: Lp-PLA(2) levels in ACS patients (median 305 ng/mL in FRISC II, 373 ng/mL in GUSTO IV)
Number of subjects: 2266
Study 17314110 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (median Lp-PLA(2) 254 ng/mL)
Number of subjects: 2266
Study 15205386 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolbutamide, Ibuprofen, Fluvastatin
Number of subjects: 0
Study 15205386 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro drug-drug interaction potential
Number of subjects: 0
Study 15205386 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin (without protein binding)
Number of subjects: 0
Study 15205386 — intervention group
Group type: EXPERIMENTAL
Intervention: Well stirred prediction model and CL(int) calculations
Number of subjects: 0
Study 11535487 — intervention group
Group type: EXPERIMENTAL
Intervention: Defibrillation as the primary treatment for VF
Number of subjects: 0
Study 11535487 — intervention group
Group type: EXPERIMENTAL
Intervention: Achieving restoration of spontaneous circulation (ROSC)
Number of subjects: 0
Study 11535487 — intervention group
Group type: EXPERIMENTAL
Intervention: Resuscitation from cardiac arrest divided into two phases
Number of subjects: 0
Study 11535487 — intervention group
Group type: EXPERIMENTAL
Intervention: Focus on heart and brain during resuscitation
Number of subjects: 0
Study 9252717 — intervention group
Group type: EXPERIMENTAL
Intervention: Ifosfamide (IFO), Vinorelbine (VNB), Cisplatin (DDP)
Number of subjects: 0
Study 9252717 — intervention group
Group type: COMPARATOR
Intervention: Ifosfamide (IFO), Vinorelbine (VNB)
Number of subjects: 0
Study 8495122 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass surgery
Number of subjects: 0
Study 3791847 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of an information leaflet
Number of subjects: 0
Study 3791847 — intervention group
Group type: COMPARATOR
Intervention: No information leaflet
Number of subjects: 0
Study 31593002 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS (5 daily sessions, 500 pulses per session at 5 Hz)
Number of subjects: 144
Study 31593002 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS (5 daily sessions)
Number of subjects: 144
Study 31593002 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS (4 weekly sessions, open-label continuous trial)
Number of subjects: 144
Study 31593002 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS (4 weekly sessions, open-label continuous trial)
Number of subjects: 144
Study 31201481 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab 60 mg every 6 months
Number of subjects: 2207
Study 31201481 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2207
Study 28797427 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level tragus stimulation (LL-TS)
Number of subjects: 95
Study 28797427 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation (Control)
Number of subjects: 95
Study 25092797 — intervention group
Group type: EXPERIMENTAL
Intervention: Rescuer-limited CPR
Number of subjects: 90
Study 25092797 — intervention group
Group type: COMPARATOR
Intervention: 2-min switched CPR
Number of subjects: 90
Study 23496803 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic dairy product (active group)
Number of subjects: 179
Study 23496803 — intervention group
Group type: COMPARATOR
Intervention: Non-probiotic dairy product (placebo group)
Number of subjects: 179
Study 21785864 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 21785864 — intervention group
Group type: EXPERIMENTAL
Intervention: Baclofen
Number of subjects: 16
Study 21785864 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 16
Study 17623246 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic colorectal resections
Number of subjects: 15
Study 17623246 — intervention group
Group type: COMPARATOR
Intervention: Conventional colorectal resections
Number of subjects: 15
Study 17135993 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma-Focused Cognitive Behavioral Therapy (TF-CBT)
Number of subjects: 183
Study 17135993 — intervention group
Group type: COMPARATOR
Intervention: Child-Centered Therapy (CCT)
Number of subjects: 183
Study 14581113 — intervention group
Group type: EXPERIMENTAL
Intervention: High frequency (110 Hz), high intensity (strong but comfortable), segmental stimulation for 30 min
Number of subjects: 240
Study 14581113 — intervention group
Group type: EXPERIMENTAL
Intervention: High frequency (110 Hz), high intensity (strong but comfortable), combined stimulation for 30 min
Number of subjects: 240
Study 14581113 — intervention group
Group type: EXPERIMENTAL
Intervention: Low frequency (4 Hz), strong but comfortable intensity, segmental stimulation for 30 min
Number of subjects: 240
Study 14581113 — intervention group
Group type: EXPERIMENTAL
Intervention: Low frequency (4 Hz), highest tolerable intensity, segmental stimulation for 30 min
Number of subjects: 240
Study 14581113 — intervention group
Group type: EXPERIMENTAL
Intervention: High frequency (110 Hz), highest tolerable intensity, segmental stimulation for 30 min
Number of subjects: 240
Study 14581113 — intervention group
Group type: EXPERIMENTAL
Intervention: Low frequency (4 Hz), strong but comfortable intensity, combined stimulation for 30 min
Number of subjects: 240
Study 14581113 — intervention group
Group type: EXPERIMENTAL
Intervention: Low frequency (4 Hz), highest tolerable intensity, combined stimulation for 30 min
Number of subjects: 240
Study 14581113 — intervention group
Group type: COMPARATOR
Intervention: Sham TENS
Number of subjects: 240
Study 8866039 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast-dissolving ketorolac tablet
Number of subjects: 12
Study 8866039 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-1 dissolving ketorolac tablet
Number of subjects: 12
Study 8866039 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-2 dissolving ketorolac tablet
Number of subjects: 12
Study 8866039 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-dissolving ketorolac tablet
Number of subjects: 12
Study 8866039 — intervention group
Group type: COMPARATOR
Intervention: All formulations
Number of subjects: 12
Study 1378148 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 14
Study 1378148 — intervention group
Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 14
Study 6848932 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey-based infant formula
Number of subjects: 60
Study 6848932 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk from mothers of preterm infants
Number of subjects: 60
Study 6848932 — intervention group
Group type: COMPARATOR
Intervention: Milk from mothers of term infants
Number of subjects: 60
Study 30769861 — intervention group
Group type: EXPERIMENTAL
Intervention: Habitual afternoon schedule
Number of subjects: 20
Study 30769861 — intervention group
Group type: COMPARATOR
Intervention: Unconventional morning schedule
Number of subjects: 20
Study 28245193 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-based problem-based learning
Number of subjects: 120
Study 28245193 — intervention group
Group type: COMPARATOR
Intervention: Paper-based problem-based learning
Number of subjects: 120
Study 25369272 — intervention group
Group type: EXPERIMENTAL
Intervention: AM3 (Inmunoferón®)
Number of subjects: 16
Study 25369272 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 24313583 — intervention group
Group type: EXPERIMENTAL
Intervention: Maltitol chewing-gum
Number of subjects: 258
Study 24313583 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylitol chewing-gum
Number of subjects: 258
Study 24313583 — intervention group
Group type: COMPARATOR
Intervention: Gum base (placebo)
Number of subjects: 258
Study 24313583 — intervention group
Group type: COMPARATOR
Intervention: No gum (negative control)
Number of subjects: 258
Study 21629020 — intervention group
Group type: EXPERIMENTAL
Intervention: Social contact with perceived close partners
Number of subjects: 197
Study 21629020 — intervention group
Group type: COMPARATOR
Intervention: Depressive symptoms
Number of subjects: 197
Study 21629020 — intervention group
Group type: COMPARATOR
Intervention: Time spent with perceived close partners
Number of subjects: 197
Study 19920413 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous preperitoneal wound infusion (CPWI) of 0.2% ropivacaine at 10 mL/hr for 48 hrs
Number of subjects: 20
Study 19920413 — intervention group
Group type: COMPARATOR
Intervention: Conventional parenteral analgesia (intravenously administered morphine via patient‐controlled analgesia and acetaminophen) without parietal analgesia
Number of subjects: 20
Study 16426099 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal depression (current major depressive episode)
Number of subjects: 0
Study 16426099 — intervention group
Group type: EXPERIMENTAL
Intervention: Atypical depressive features in mothers
Number of subjects: 0
Study 16426099 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal history of suicide attempts
Number of subjects: 0
Study 16426099 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal comorbid panic disorder with agoraphobia
Number of subjects: 0
Study 16426099 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal irritable depression
Number of subjects: 0
Study 16426099 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal substance use disorders
Number of subjects: 0
Study 15700916 — intervention group
Group type: EXPERIMENTAL
Intervention: Cessation treatment for smokers with past major depressive disorder
Number of subjects: 85
Study 12567752 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh corneas
Number of subjects: 36
Study 12567752 — intervention group
Group type: COMPARATOR
Intervention: Cryopreserved corneas
Number of subjects: 36
Study 8510514 — intervention group
Group type: EXPERIMENTAL
Intervention: 23 g parboiled white rice (20 g available carbohydrate)
Number of subjects: 7
Study 8510514 — intervention group
Group type: EXPERIMENTAL
Intervention: 46 g parboiled white rice (40 g available carbohydrate)
Number of subjects: 7
Study 8510514 — intervention group
Group type: EXPERIMENTAL
Intervention: 69 g parboiled white rice (60 g available carbohydrate)
Number of subjects: 7
Study 8510514 — intervention group
Group type: COMPARATOR
Intervention: Control for glucosuria after 20 g carbohydrate
Number of subjects: 7
Study 8510514 — intervention group
Group type: COMPARATOR
Intervention: Control for glucosuria after 40 g carbohydrate
Number of subjects: 7
Study 8510514 — intervention group
Group type: COMPARATOR
Intervention: Control for glucosuria after 60 g carbohydrate
Number of subjects: 7
Study 3327883 — intervention group
Group type: EXPERIMENTAL
Intervention: Spiramycin
Number of subjects: 1
Study 3327883 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1
Study 29447382 — intervention group
Group type: EXPERIMENTAL
Intervention: Group acupuncture (20 treatments over 10 weeks, 900 minutes total)
Number of subjects: 30
Study 29447382 — intervention group
Group type: COMPARATOR
Intervention: Group education (20 sessions over 10 weeks, 900 minutes total)
Number of subjects: 30
Study 27309790 — intervention group
Group type: EXPERIMENTAL
Intervention: Education based on the Roy Adaptation Model
Number of subjects: 82
Study 27309790 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 82
Study 26526558 — intervention group
Group type: EXPERIMENTAL
Intervention: Transperineal biopsy (TPBx)
Number of subjects: 339
Study 26526558 — intervention group
Group type: COMPARATOR
Intervention: Transrectal biopsy (TRBx)
Number of subjects: 339
Study 24340417 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitated FCR with bunnies
Number of subjects: 0
Study 24340417 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitated FCR with clowns
Number of subjects: 0
Study 24340417 — intervention group
Group type: COMPARATOR
Intervention: Usual care model facilitated by distracted residents and overbearing attending physicians
Number of subjects: 0
Study 20179903 — intervention group
Group type: EXPERIMENTAL
Intervention: Retropubic or transobturator sling procedure
Number of subjects: 537
Study 20179903 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 537
Study 17712352 — intervention group
Group type: EXPERIMENTAL
Intervention: LY544344 16 mg b.i.d.
Number of subjects: 108
Study 17712352 — intervention group
Group type: EXPERIMENTAL
Intervention: LY544344 8 mg b.i.d.
Number of subjects: 108
Study 17712352 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study 16671425 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (IND) 100 mg transrectally and 6 mg/kg/day for 14 days
Number of subjects: 46
Study 16671425 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (IND) 6 mg/kg/day for 14 days
Number of subjects: 46
Study 16671425 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (IND)
Number of subjects: 46
Study 14654744 — intervention group
Group type: EXPERIMENTAL
Intervention: Active antihypertensive treatment
Number of subjects: 744
Study 14654744 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 744
Study 10380022 — intervention group
Group type: EXPERIMENTAL
Intervention: C3F8 gas (22 eyes)
Number of subjects: 47
Study 10380022 — intervention group
Group type: COMPARATOR
Intervention: Silicone oil (25 eyes)
Number of subjects: 47
Study 9373658 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine (CQ)
Number of subjects: 289
Study 9373658 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrimethamine/Sulfadoxine (PS)
Number of subjects: 289
Study 9373658 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefloquine (15 mg base/kg)
Number of subjects: 289
Study 8385430 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-886 (500 mg and 250 mg)
Number of subjects: 8
Study 8385430 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 3083727 — intervention group
Group type: EXPERIMENTAL
Intervention: Group I (n = 6) with PaCO2 levels of 36 +/- 4 mmHg and 42 +/- 4 mmHg
Number of subjects: 12
Study 3083727 — intervention group
Group type: EXPERIMENTAL
Intervention: Group II (n = 6) with PaCO2 levels of 47 +/- 3 mmHg and 53 +/- 3 mmHg
Number of subjects: 12
Study 31112952 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid Laparoendoscopic Single-Site Surgery (hLESS)
Number of subjects: 61
Study 31112952 — intervention group
Group type: COMPARATOR
Intervention: Conventional Three-Port Laparoscopy (TPL)
Number of subjects: 61
Study 27100959 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (50 mg three times a day for 1 year)
Number of subjects: 81
Study 27100959 — intervention group
Group type: COMPARATOR
Intervention: Observation (standard care)
Number of subjects: 81
Study 26620151 — intervention group
Group type: COMPARATOR
Intervention: GSK2256294 2-20 mg single escalating doses
Number of subjects: 0
Study 26620151 — intervention group
Group type: COMPARATOR
Intervention: GSK2256294 6 or 18 mg once daily for 14 days
Number of subjects: 0
Study 26620151 — intervention group
Group type: COMPARATOR
Intervention: GSK2256294 10 mg single dose
Number of subjects: 0
Study 26620151 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24823461 — intervention group
Group type: EXPERIMENTAL
Intervention: GH treatment: 33 or 67 μg/kg · d
Number of subjects: 151
Study 24823461 — intervention group
Group type: COMPARATOR
Intervention: Untreated controls
Number of subjects: 151
Study 22107076 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity intervention
Number of subjects: 171
Study 22107076 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental activity intervention
Number of subjects: 171
Study 22107076 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping plans
Number of subjects: 171
Study 22107076 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping plans in exercise condition
Number of subjects: 171
Study 20234892 — intervention group
Group type: EXPERIMENTAL
Intervention: Prime and Bond adhesive using the immediate dentin sealing (IDS) technique
Number of subjects: 25
Study 20234892 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated teeth)
Number of subjects: 25
Study 18661687 — intervention group
Group type: EXPERIMENTAL
Intervention: 12.5 mg of HBB plus 2.5 microg of intrathecal sufentanil
Number of subjects: 100
Study 18661687 — intervention group
Group type: EXPERIMENTAL
Intervention: 12.5 mg of HBB plus 5 microg of intrathecal sufentanil
Number of subjects: 100
Study 18661687 — intervention group
Group type: COMPARATOR
Intervention: 12.5 mg of HBB
Number of subjects: 100
Study 18661687 — intervention group
Group type: COMPARATOR
Intervention: 12.5 mg of HBB plus 5 microg of subcutaneous sufentanil
Number of subjects: 100
Study 15968954 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 microg intramuscular hepatitis B vaccine (group 1)
Number of subjects: 86
Study 15968954 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 microg intradermal hepatitis B vaccine (group 2)
Number of subjects: 86
Study 12697108 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive prevention of cerebrovascular diseases (1987 - 2000)
Number of subjects: 0
Study 12697108 — intervention group
Group type: COMPARATOR
Intervention: Control cohort (no intervention)
Number of subjects: 0
Study 12697108 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention cohort
Number of subjects: 0